Mice with or without immunosuppression by cyclosporin (Cy) were inoculated with herpes simplexvirus type 1 in the ear pinna. Without immunosuppression, 20% of the mice died; clinical signs resolved in survivors and infectious viruswas cleared by 7 to 10 days post-inoculation (p.i.). With Cy, mortality was 50%, clinical signs increased and infectious virus persisted. Mice were treated with either valaciclovir (VACV) or famciclovir (FCV) from days 1-50r 5-10 p.i. and both compounds moderated the disease, but only FCV led to rapid restoration of body weight ond complete protection from mortality. Resolution of clinical signs was more marked with immunosuppression. On cessation of VACV theropy, infectious virus recurred on individual days. Without immunosuppression, recurrence was detected in neural tissues only, but with Cy, infectious virus also recurred in skin. No recurrences of infectious virus were observed in any FCV-treated mice.
Introduction
During the period of clinical experience of herpes simplex virus (HSV) treatment with acyclovir [9-(2-hydroxyethoxymethyl)guanine; ACV] it has become apparent that chemotherapy is very effective in the immunocornpromised patient (Prober et al., 1982; Wade et al., 1982; Meyers et al., 1988) . Apart from the problem of resistance development (Marshall, 1983; Watson, 1983; Reusser et al., 1996) , both prophylactic and therapeutic ACV have been effective in preventing clinical signs and virus shedding from the chronic lesions that are prone to occur in such patients. It appears that an intact immune system is not essential in order to reduce active HSV infection from the tissues by means of ACV chemotherapy. A number of published reports have employed animal models to research the particular problems associated with chemotherapy in severely immunocompromised patients (Ellis et al., 1989a,b) . To date however, there are only a few reports on penciclovir (PCV) and famciclovir(FCV) therapy in immunocompromised patients.
Cyclosporin (Cy), given on alternate days, has the specific effect of reducing T cell function in mice and this results in chronic virus replication in both peripheral tissues and the central nervous system (CNS) (Hill et al., 1975; Fazakerley & Webb, 1985 Berkowitz-Balshayi et al., 1995) . The oral prodrugs FCV and valaciclovir (VACV) provide high bio-availability of PCV and ACV, respectively, and we have shown previously that both are effective in our murine immunosuppression model .
Our previous experiments, however, did not maintain immunosuppression beyond 10 days post-inoculation (p.i.) (the latest time at which chemotherapy was terminated). Furthermore, the experiments were not internally controlled to examine the relative effectiveness of chemotherapy in mice with and without immunosuppression. The experiments described in this paper examine both these issues and demonstrate clearly some important interactions between the virus inhibitors and immunosuppression that may be relevant to the use of antiviral chemotherapy in man.
Materials and Experimental Procedures
Virus strain and tissue culture The virus used was HSV-1 strain SC16. This strain of virus has been extensivelycharacterized in mice (Hill et al., 1975) and has been used previously for studying antiviral compounds (Field et al., 1979 , 1995j Boyd et al., 1988 Sutton & Boyd, 1993) .
Mice and virus inoculation
A total of 780 female 4-week-old BALBlc mice (Bantin and Kingman, Kingston, UK) were inoculated into the skin of the left ear pinna with lx10 5 p.£u. HSV-1 (SC16) per ear using previouslypublished methods .
Induction of immunosuppression
Cywas obtained at 50 mg mL-I in polyethoxylated castor oil (Sandimmun; Sandoz Pharmaceuticals, Camberley, UK). Cy was diluted in sterile PBS, homogenized using an Ultra-turrax and then sonicated in order to mix thoroughly the two solutions. It was given by subcutaneous injection on alternate days starting from 2 days prior to virus inoculation and continuing until day 20 p.i. at a dose of 50 mg kg-I in 0.1 mL.
Measurement of clinical signs
Mice were assessed subjectively once per day and signs of clinical disease noted. Mice with a flaccid ear pinna that failed to respond to a gende stimulus were recorded as showing 'ear paralysis'. Other neurological signs were recorded including circling, unsteady gait and monolateral and bilateral hindlimb paralysis. Skin thickness was measured daily in individual mice by means of an engineers' micrometer screw gauge. Mean values with SD were cal-culated from groups of eight mice. Mortality was assessed separately using groups of 20 mice. These methods have been described in detail previously (Field et al., 1979) .
Titration of virus in tissue samples
Tissue samples (ear pinna or brain stem) were obtained from three mice for each treatment on each day from day 1-20 p.i. inclusive. Each tissue sample was homogenized and titrated independently for infectious virus using a plaque assay on monolayers ofBHK-21 cells as previously described . All tissues were coded prior to testing and the code was not broken until all samples had been titrated.
Antiviral compounds and treatment regimen
FCV and VACV were supplied by SrnithKline Beecham (Brentford, UK). The activity of ACV and PCY, which are the activemetabolites ofVACV and FCY, respectively, were measured by means of a plaque reduction assayin BALBlc 3T3 cells. The 50% effective doses(±SD) were 0.OhO.01 and 0.02±0.01 flg mL-I for ACV and PCY, respectively .FCV and VACVwere dissolved in double-distilled deionizedwater and were administeredby oral gavage(50 mg kg-I), twicedailyfrom 22 h p.i. up to and including day 5 p.i., or from day 5 to 10 p.i. inclusive.
Results

Effects of Cy immunosuppression on H5V-l pathogenesis
Clinical signs. The administration of Cy had a marked effect on the incidence, intensity and duration of clinical with immunosuppression, however, all clinical signs continued in surviving mice until the end of observation (Table 1) .
Mortality. Without Cy, 4/20 (20%) mice died by day 14 p.i, after which time no further deaths occurred. The mean time to death was 10.8 days (range 10 to 13 days). With Cy immunosuppression, mortality reached 40% by day 14; furthermore, mice continued to die and the cumulative mortality was 50% by day 20 p.i., such that the mean time to death was 10.7 (range 8 to 16 days) ( Table 1) .
Weight retardation. After virus inoculation all mice lost weight for 2-3 days and weight gain remained retarded to day 20 p.i, The loss of weight at day 2 was approximately 6% in infected mice without immunosuppression ( Fig. 1 ), but 29% in mice that received Cy. Furthermore, at day 20 p.i., Cy-treated mice remained approximately 20% underweight. Cy produced no overt toxicity,and in the uninfected control mice the administration of Cy produced no significant change in weight gain; the weight of the Cy-treated mice remained slighdy below the uninfected untreated controls throughout the period of observation ( Fig. 1 ). The negative controls (both with and withoutCy) have been repeated in the middle and lower panels to facilitate comparison of the data. Inflammation ifthe em: Within 1 day of virus inoculation the infected ear pinna became inflamed and this was measured quantitatively by means of skin thickness. The administration of Cy had little effect on ear thickness to day 9 p.i. (Fig. 2) . Thereafter, the ear thickness returned to near normal values except in Cy-treated mice. In these mice, thickness continued to increase to day 14, and remained at an approximate threefold increase above the normal mean value at 20 days p.i. tissues, to levels below that of the sensitivity of the assay, by days 7 and 10 p.i. (from the ear and brain stem, respectively). The administration of Cy had a marked effect on virus titres in both the skin and the brain stem. The levels of infectious virus remained high in both sites, with titres of3.5 to 4.5 loglO per tissue in surviving mice at day 20 p.i.
Effects of systemic antiviral chemotherapy on infection with or without immunosuppression
Virus growth in tissue. Virus titres were maximum on days 3 and 6 p.i. in the ear and brain stem samples, respectively (Figs 3 and 4 ). Without immunosuppression, virus titres declined sharply and virus was cleared from these Clinical signs.Although antiviral therapy (without immunosuppression) from 22 h p.i. ablated the appearance of most clinical signs, ear paralysis occurred in 30% of untreated mice, 40% with FCV treatment and 50% with VACV therapy (Table 1) . However, in Cy-treated mice, there was a clear effect of therapy such that 100% of control mice showed ear paralysis,which was reduced to 15% and 30% by early treatment with FCV or VACV, respectively. When treatment started on day 5 p.i., FCV was effective in moderating clinical signs both with and without concurrent Cy treatment (Table 1) . With VACV, moderation of clinical signs was observed in Cy-treated mice, but not in normal, non-immunosuppressed animals (Table 1) .
Mortality. Early therapy with either compound completely prevented mortality. However, in mice treated from days 5-10, VACV did not completely prevent death and it was notable that more mice (25%) died in the VACV-treated group that were not immunosuppressed (mean time to death was 14.6 days with a range of 14 to 16 days), than in the Cy-treated group (10%) (mean time to death was 14.5 days with a range of 14 to 15 days). In both cases mice died several days after cessation of the VACV therapy. FCV therapy, starting early or late, completely prevented mortality in normal and immunosuppressed mice.
Weight retardation. Chemotherapy with FCV produced a very rapid resumption of weight gain. In mice that received Cy, weight quickly regained or exceeded that of uninfected controls (Fig. 1) . VACV had much less effect and mice remained below normal weight; again the best response to VACV therapy was observed in mice that received Cy.
Inflammation of the em: Early therapy with either drug markedly reduced inflammation in the infected ear ( Fig. 2a ). This effect was greatest in Cy-treated mice and was particularly marked in Cy-treated mice receiving VACV. In VACV-treated non-immunosuppressed mice, ear thickness remained significantly above the uninoculated controls at late times after inoculation. In contrast, ear thickness in FCV-treated mice remained close to control levels for the duration of the study. Late treatment also reduced ear thickness both with and without Cy. In this case, the most rapid response was seen in mice that did not receive immunosuppression. However, as with the early treatment, the best and most prolonged response to VACV occurred in mice that received Cy (Fig. 2b) . FCV therapy gave sustained reduction in both immunosuppressed and normal mice.
Virus growth in the em: Early therapy reduced virus repli-cation in the skin and accelerated the clearance of infectious virus. During therapy from days 1-5, FCV and VACV were similar in their effects on virus titres in the ear (Fig. 3a) . However, at the end of therapy on day 5, a marked difference between the compounds was apparent. In FCV-treated groups that received Cy, virus clearance was completed by day 7 p.i. (two days after cessation of therapy). In contrast, VACV-treated mice did not clear the infection and the samples were positive for all mice tested on days 9 and 12 p.i. Treatment commencing on day 5 p.i. was required for 3 and 4 days for FCV-and VACV-treated mice respectively, to clear virus from the skin of immunosuppressed mice (Fig. 3b) . A further group of three Cy-treated mice were all seen to contain virus on day 16, 6 days following termination of VACV. No late recurrence of infectious virus was observed in mice that had not been given Cy, or in any mice treated with FCV.
Virus growth in the brain stem. Early therapy did not completely prevent virus replication in the brain stem and low titres were observed on days 5 or 6 p.i. (towards the end of the treatment period; Fig. 4a ). In contrast to FCV, there was a recurrence of infectious virus in both VACVtreated groups; on day 10 with Cy treatment, and days 9 and 10 without Cy treatment (Fig. 4a ). Similar results were obtained with the two compounds when treatment was delayed to days 5-10 p.i., where multiple recurrences of infectious virus were observed in VACV-tn;:ated mice following termination of therapy on day 10 p.i. (Fig. 4b ).
There was no recurrence of infectious virus in any FCVtreated group.
It was notable that in the brain stem, recurrences of infectious virus after VACV therapy occurred irrespective ofwhether mice did or did not receive Cy.The recurrences were not, however, exactly co-incident in the two groups. Recurrence of infectious virus was also observed on day 14 p.i. in the trigeminal ganglia of Cy-treated mice after cessation ofVACV (data not shown).
Discussion
One important result from this study was the demonstration that FCV or VACV therapy was highly effective for treating HSV-l in irnmunocompromised mice. Not only was virus rapidly cleared from the target tissues, but clinical signs did not progress during a period of 2 weeks following cessation of therapy, although the immunosuppressive regimen was continued to day 20 p.i. Interestingly, there was a transient, but reproducible resurgance of virus replication following cessation of VACV, but not FCV, treatment. These observations confirmed results which have been published earlier Field & Antiviral Chemistry &Chemotherapy 8(4) The effects of cyclosporin on HSV-l antiviral theropy , in which immunosuppression was terminated on day 10.
In the present study, the most noticeable effect of Cy was to exacerbate the clinical signs associated with HSV-l infection. All were increased in both intensity and duration. Furthermore, infectious virus replication continued in skin and neural sites up to day 20 p.i. This was therefore considered to be a good model for chronic HSV-l infection in which to test antiviral chemotherapy.
It has been demonstrated that, in the mouse, Cy enhanced the T-cell-mediated demyelinating meningoencephalomyelitis induced by Semliki Forest virus infection (Fazakerley & Webb, 1987) . When Cy was given at 50 mg kg-1 per day starting from 2 days before virus infection, there was a marked suppression of early antibody synthesis, as seen by the high and prolonged virus titres in the blood and brain. In addition, the inflammatory response in the brains of these mice was not suppressed, but enhanced. Our data are consistent with these findings.
It has been reported that Cy was undetectable in the cerebrospinal fluid of mice after oral administration and therefore any lymphocytes that were recruited to the CNS from the blood escaped the drug's immunosuppressive effect (Fazakerley & Webb, 1987) . The increased inflammatory response probably represented a reaction by the non-suppressed CNS lymphocytes to the increased number of virus-infected cells. A similar increased CNS inflammation was apparent, with high brain virus titres, following cyclophosphamide immunosuppression of Semliki Forest virus-infected mice (Webb & Jagelman, 1979; Berger, 1980) . The effect of Cy seems to be determined by the time of drug administration relative to the course of the immune response.
Previous studies reported enhanced replication of HSV-l in mice treated with Cy (Berkowitz-Balshayi et al., 1995; Bishop & Hill, 1991) . However, Bishop & Hill (1991) reported that clinical signs and neurological damage were reduced. This is different from our observations, but the dose and timing of Cy administration were different; they reported that intraperitoneal administration of 200 ilL of a 10% solution of Cy at day 2,4 or 6 after inoculation with HSV-l caused a significant reduction in the incidence of ear paralysis, with no effect observed when treatment was administered on day 0 or 8 p.i. In our experiments, Cy was repeatedly administered subcutaneously at 50 mg kg-1 in 0.1 mL on alternate days starting 2 days prior to virus inoculation. In agreement with Bishop & Hill (1991) , our study indicates that a peripheral HSV-l infection is markedly influenced by the immune status of the mouse. Our data suggest that in conjunction with early administration of either FCV or VACV, the early use of Cy gives rise to favourable reductions in both clinical signs and virus titres in the ear and brain stem.
As previously reported by Bishop & Hill (1991) , the late administration of Cy following an HSV-1 infection appeared to have no effect on the progression of the disease, suggesting that Cy acts on the immunocompetent cells at an early stage in antigenic triggering.
Pharmacokinetic studies suggested that following an oral dose of 50 mg kg-l, blood levels of ACV or PCV were very similar and in both cases the blood concentration fell below the level of detection «0.2 Ilg mL-l) within 3-8 h after oral administration of the prodrug. Since mice in this experiment were given drug at 8 am and 6 pm, a period of 14 h elapsed between doses. During this time it would be expected that drug levels in the blood would remain below the effective inhibitory concentrations of either compound for several hours. ACV and PCV have similar antiviral activity against HSV-1 in tissue culture measured in murine 3T3 cells. The most likely explanation for the superiority ofFCV is the relative longevity of PCV-triphosphate in virus-infected cells in comparison with ACV-triphosphate (approximately 10 h versus approximately 0.7-1 h, respectively; Vere Hodge & Perkins, 1989; Earnshaw et al., 1992; Vere Hodge & Cheng, 1993) . This was fll'St suggested by Larsson et al. (1986) , Datema et al. (1987) and Boyd et al. (1987) . More recent experiments in murine models for systemic HSV infection provided further weight for this hypothesis (Boyd et al., 1988; Sutton & Boyd, 1993; Ashton et al., 1994) . Several workers have reported an effect of PCV in tissue culture that appeared to persist for up to several days after removal of the drug (Weinberg et al., 1992; Bacon & Schinazi, 1993; Standring-Cox et al., 1994; Bacon & Howard, 1996) .
In the current report, the differences between the compounds were most notable in terms of their effects on mortality, weight loss and inflammation of the infected ear.The two compounds showed a similar ability to reduce the titres of infectious virus in murine tissues. After cessation ofVACV therapy, however, individual groups of mice were found to contain high levels of infectious virus on individual days. No such rebound occurred following the end of FCV treatment. A curious feature of this occurrence was that in all cases, the three mice in the particular experimental group were positive on the same day, with .closely similar virus titres. Why this should be so remains a mystery but similar findings have been reported previously Thackray & Field, 1996) . Our interpretation of these results is that infectious virus production can recur following the slow decay of the ACV-triphosphate-induced inactivation of HSV-1 DNA polymerase within infected cells, rather than any decline in immune clearance. We believe that the latter would produce a more varied and sporadic occurrence of virus. Alternatively, there may be a difference between ACV and PCV in the viability of HSV-1-infected cells in 324 the presence of inhibitory concentrations of compound. It was notable that the recurrence of infectious virus in the ear pinna ofVACV-treated mice occurred only in the Cytreated group, although the reappearance of infectious virus was transient despite the continued application of Cy. However, infectious virus was detected in brain stem at late times with and without Cy. It is likely that recurrence occurs in neural tissue and the infectious virus is transported to the ear by rapid axonal flow from the nervous system into the skin. In normal mice, the immune/inflammatory response in the local tissue is better able to eliminate recurrent virus in skin than in immunosuppressed mice.
When the effects of VACV or FCV on the infection were compared, with or without Cy, it was seen that the intact immune system was not required for resolution of clinical signs and reduction ofinfectious virus by means of chemotherapy. Indeed, in relation to mortality and weight loss, the antiviral compounds produced greater effects with Cy in all cases. Since immunocompetent mice clear the infection spontaneously, the reduction in virus titre with or without Cy could not be readily compared. Immunosuppression however, did not appear to allow a significantly greater loglo reduction in virus titre. In previous experiments , we have seen larger reductions in Cy-treated mice than those reported here; however, the infections were not internally controlled as is the case in the present study.
The very rapid effects of FCV on weight loss (which returned to normal within 1-2 days of commencing treatment) were remarkable. VACV produced a markedly beneficial effect on weight loss only in immunosuppressed mice. The cause of weight loss in infected mice is unknown but it appears to be a reflection of the general well-being of the animals and may be a sensitive indicator of the success of antiviral chemotherapy, especially relating to virus replication and damage produced in the nervous system. Finally, the experiments described in this report produce several observations that may be relevant to the treatment of HSV infections in man. The results suggest that the Cy infection model can be used to explore the relative efficacy of different therapeutic regimens under development for treating infections in the irnmunocompromised host. Clearly, the correct extrapolation to man is dependent on accurate knowledge of the pharmacodynamics of the compounds in mice as well as a thorough understanding of the pathogenesis of the infection. This information is not yet complete and therefore the results must be viewed with caution, especially when attempting to make a direct comparison between two different prodrugs. The data do however raise questions concerning the factors that may limit the success ofantiviral therapy; for example, the recurrence of virus replication once therapy stops.
Although clinical trials may be closely monitored, it is extremely difficult to obtain quantitative virological data from the target tissues in man. Therefore, further experiments are in hand using the murine model to explore the different effects of these important antiherpesvims agents. 
